{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:16:32Z","timestamp":1784128592001,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Quality of life and symptom burden of patients with myelofibrosis are well recognized and compounded in those with anemia; however, the effects of transfusion burden or anemia severity on quality of life have not been comprehensively characterized. This post hoc descriptive analysis explored the association between transfusion status or hemoglobin improvement and patient\u2010reported outcomes (PROs).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The analysis used pooled populations across treatment arms from 3 clinical trials (SIMPLIFY\u20101, SIMPLIFY\u20102, MOMENTUM); sample sizes for each PRO measure were dependent on the trials in which they were administered.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At both baseline and week 24, transfusion independence was associated with umerically greater mean\n SF<\/jats:styled-content>\n \u201036v2 and\n EORTC QLQ<\/jats:styled-content>\n \u2010\n C30<\/jats:styled-content>\n scores than transfusion dependence; in the subgroup that was transfusion dependent at baseline, those who achieved transfusion independence at week 24\u2009had greater\n PRO<\/jats:styled-content>\n improvements than those who remained reliant on transfusions. Regardless of transfusion status, patients who achieved a hemoglobin improvement \u2265\u20091, \u2265\u20091.5, or \u2265\u20092\u2009g\/\n dL<\/jats:styled-content>\n from baseline also had clinically meaningful improvements in quality of life (assessed via mean\n EQ<\/jats:styled-content>\n \u2010\n 5D<\/jats:styled-content>\n \u2010\n 5L<\/jats:styled-content>\n or\n SF<\/jats:styled-content>\n \u201036v2 scores) and symptoms (assessed via\n PGIC<\/jats:styled-content>\n or\n MPN<\/jats:styled-content>\n \u2010\n SAF<\/jats:styled-content>\n \/\n MFSAF<\/jats:styled-content>\n Total Symptom Score) at week 24 compared with those who did not.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Collectively, these results provide preliminary insights into the associations of transfusion status and anemia severity with quality of life in myelofibrosis; as current PRO measures do not directly evaluate the relationship between symptoms such as fatigue and anemia, development of new measures to more comprehensively capture the patient experience for those with anemia in myelofibrosis may be warranted.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n NCT01969838, NCT02101268, NCT04173494<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.71729","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:40:58Z","timestamp":1775810458000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association Between Transfusion Status, Hemoglobin Levels, and Patient\u2010Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"first","affiliation":[{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Mayo Clinic Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010 Universitaria di Bologna, Istituto di Ematologia, S. Orsola\u2010Malpighi Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Mazerolle","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a THREAD company Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"M'hari","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a THREAD company Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Liu","sequence":"additional","affiliation":[{"name":"GSK Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"GSK Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cardellino","sequence":"additional","affiliation":[{"name":"GSK Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"GSK Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Ellis","sequence":"additional","affiliation":[{"name":"GSK Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaipayan","family":"Patnaik","sequence":"additional","affiliation":[{"name":"GSK Baar Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Regnault","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a THREAD company Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2208-2"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1480768"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","unstructured":"G.Caocci F.Palandri G. G.Loscocco et\u00a0al. \u201cHealth\u2010Related Quality of Life and Symptom Burden Profile of Patients With Pre\u2010Fibrotic and Overt Myelofibrosis: A Preliminary Report From the GIMEMA\u2013Prophecy Observational Study \u201dPresented at: 65th ASH Annual Meeting and Exposition; December 9\u201012 2023; San Diego CA Poster 2441 (2023).","DOI":"10.1182\/blood-2023-186429"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1827-2"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3380"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113325"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000966"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.012"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_2_12_15_1","unstructured":"A. T.Gerds C.Harrison S.Thompson F.Snopek andN.Pemmaraju \u201cThe Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States \u201dPresented at: 64th ASH Annual Meeting and Exposition; December 10\u201013 2022; New Orleans LA Poster 1729 (2022)."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2368450"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","unstructured":"A.Cardellino H.Collacott S.Zhang K.Phiri V.Turner andM.Ross \u201cPatient Experience With and Perceptions of Transfusion\u2010Dependent and Transfusion\u2010Independent Myelofibrosis: A Qualitative Interview Study \u201dPresented at: 29th EHA Congress; June 13\u201016 2024; Madrid Spain and Online Poster P1686 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.e23110"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","unstructured":"T. W.LeBlanc H.Collacott V.Garcia Gutierrez et\u00a0al. \u201cExperienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self\u2010Report Survey Analysis \u201d Presented at: 66th ASH Annual Meeting and Exposition; December 7\u201010 2024; San Diego CA Poster 3815 (2024).","DOI":"10.1182\/blood-2024-206086"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.016"},{"key":"e_1_2_12_22_1","volume-title":"Omjjara (Momelotinib). Summary of Product Characteristics","year":"2024"},{"key":"e_1_2_12_23_1","volume-title":"Ojjaara (Momelotinib). Prescribing Information","year":"2023"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.015"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-70"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160"},{"key":"e_1_2_12_31_1","volume-title":"User's Manual for the SF\u201036v2 Health Survey","author":"Mariush M. E.","year":"2011"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","unstructured":"R.Mesa V.Gupta J.Mascarenhas et\u00a0al. \u201cAssessment of Minimal Clinically Important Difference in Patient\u2010Reported Myelofibrosis\u2010Associated Symptoms Using an Anchor\u2010Based Analysis Based on MANIFEST Arm 3 Data \u201dPresented at: 65th ASH Annual Meeting and Exposition; December 9\u201012 2023; San Diego CA Poster 3195 (2023).","DOI":"10.1182\/blood-2023-179924"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025802"},{"key":"e_1_2_12_36_1","unstructured":"S.Verstovsek S. T.Oh J. J.Kiladjian et\u00a0al. \u201cTransfusion Independence Response as a Potential Surrogate for Overall Survival in JAKi\u2010Experienced Patients With Myelofibrosis From MOMENTUM \u201dPresented at: 64th ASH Annual Meeting and Exposition; December 10\u201013 2022; New Orleans LA Poster 3028 (2022)."},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","unstructured":"S.Oh R.Mesa C.Harrison et\u00a0al. \u201cRetrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST\u20102 Trial \u201dPresented at: SOHO 2022 Annual Meeting; September 28\u2010October 1 2022; Houston TX Poster MPN\u2010145 (2022).","DOI":"10.1016\/S2152-2650(22)00954-5"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_2_12_44_1","first-page":"1","article-title":"Reflections on Estimands for Patient\u2010Reported Outcomes in Cancer Clinical Trials","volume":"35","author":"Lawrance R.","year":"2023","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30319-3"},{"issue":"3","key":"e_1_2_12_46_1","first-page":"13","article-title":"The Functional Assessment of Cancer Therapy\u2010Anemia (FACT\u2010An) Scale: A New Tool for the Assessment of Outcomes in Cancer Anemia and Fatigue","volume":"34","author":"Cella D.","year":"1997","journal-title":"Seminars in Hematology"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4489"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000562"},{"key":"e_1_2_12_49_1","doi-asserted-by":"crossref","unstructured":"P.Bose N.Gagelmann V.Gupta et\u00a0al. \u201cEfficacy of Pacritinib for Spleen Symptoms and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum \u201dPresented at: SOHO 2023 Annual Meeting; September 6\u20109 2023; Houston TX Poster MDS\u2010460 (2023).","DOI":"10.1016\/S2152-2650(23)00615-8"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29753"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003364"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1549023"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:07:34Z","timestamp":1777007254000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/cam4.71729"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71729","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71729"}}